Monday, November 21, 2011 - Before Market Open

Introductory Coverage

New "Trading Alert"

Viral Genetics, Inc.

(PK: VRAL - $.0229 per share)

www.ViralGenetics.com

Innovative Research Developed from Patent Rights for "Targeted Peptides" and "Metabolic Disruption" Bring Investors Back to VRAL

Buy Alert: Technical Reversal: 52-Week Chart on VRAL

Today's new "Trading Alert" is Viral Genetics, Inc. (OTCPK: VRAL).  The technical turnaround and uptrend recently established in VRAL stock has been confirmed by strong volume which has generated a buy signal to us on the charts.  The latest research report by Zack's Research still maintains a .15 price target over the next 12 months.

Research reports: http://www.viralgenetics.com/investors/researchreports.php

Viral Genetics discovers drug therapies from two platform technologies based on over 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant cancer. A majority-owned subsidiary, VG Energy (www.vgenergy.net), is dedicated to exploring biofuel and agricultural applications for the MDT platform.

We have included more information on the Company below, and encourage members to take a serious look at the stock of Viral Genetics (VRAL).

COMPANY BACKROUND

Viral Genetics, Inc. is a biotechnology research and development company researching new treatments and methods of detection for HIV/AIDS, Lyme Disease, staph and strep, cancer and certain other autoimmune and infectious diseases. Two approaches based on patent rights licensed from the University of Colorado and University of Vermont form the basis of our research: "Targeted Peptides" and "Metabolic Disruption". As we near completion of our preclinical research, we are preparing pre-IND applications for FDA clinical trials of compounds from these approaches in the US .

Our vision is to build on the innovative research being conducted by Dr. M. Karen Newell- Rogers, by developing the technology from the laboratory stage through to clinical trials and seeking partners for late-stage clinical development. Dr. Newell-Rogers's work in the areas of Targeted Peptides Technology (TPT) and Metabolic Disruption Technology (MDT) are revealing new facets of many diseases and the body's response to them. In doing so, we believe that her work is outlining solutions to some of the world's major health challenges including HIV/AIDS, drug-resistant cancers and autoimmune disease. 

We entered into a series of agreements with the University of Colorado and Dr. Newell-Rogers that, over time and after much successful hard work, culminated in the two Exclusive License Agreements that now form the basis of our intellectual property portfolio and our ongoing R&D efforts. Part of this included expanding our technology to include a new line of research relating to Metabolic Disruption (MDT) - an area that holds promise in cancer therapy, wound healing and - to our surprise - production of plant oils and biofuels.

We are now focused on initiating clinical trial testing of compounds for HIV/AIDS, Lyme Disease, Staphylococcus, Streptococcus and Sepsis infection, glioblastoma (a form of brain cancer), and more. We are also commencing development of the biofuels applications of the MDT patents through our separate subsidiary, VG Energy.

About Viral Genetics, Inc.

San Marino , California-based Viral Genetics discovers drug therapies from two platform technologies based on over 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant cancer. A majority-owned subsidiary, VG Energy (www.vgenergy.net), is dedicated to exploring biofuel and agricultural applications for the MDT platform. For more information, visit www.viralgenetics.com.

About VG Energy

VG Energy Inc. is an alternative energy and agricultural biotech company that is a majority-owned subsidiary of Viral Genetics Inc. Using its Metabolic Disruption Technology (MDT), Viral Genetics' cancer research led to discoveries with major consequences in a wide variety of other industries, including production of biofuel and vegetable oils. VG Energy holds the exclusive worldwide license to the MDT patent rights for use in the increase of production of various plant-derived oils from algae and seeds. Application of MDT technology to the biofuel industry could potentially allow it to overcome its major obstacle in the area of production efficiency: namely, an increase in production yields leading to feasible economic returns on investment, allowing renewable biodiesel to be competitive with fossil fuels. For more information, please visit www.vgenergy.net.

DEFINITION: "Trading Alert"

"Trading Alert" - A stock introduced to our members supported by research provided by a respected third party.  These are companies that we believe are worthy of investment, and we expect a big move up particularly in the extreme short-term.  These stocks have not been thoroughly researched by our staff, and therefore are not supported by a more in-depth profile. 

Compensation and Other Disclosures

The content of this message is published by Imperial Consulting Network Inc. and sent to select email lists through Lake Group Media, Inc. (" Lake") to provide readers with information on selected publicly traded companies. Factual information is obtained from public filings and other sources deemed to be reliable; however, neither Imperial Consulting Network Inc. nor Lake takes responsibility for verifying the accuracy of such information and they make no representation that such information is accurate or complete. Certain of the statements in this Update may be considered forwarded looking statements. Imperial Consulting Network Inc. and Lake makes no representation and provides no assurance or guaranty that such forward looking statements will prove to be accurate. See the company's filings with the Securities and Exchange Commission for factors that may cause results to be significantly different. Statements of opinion and belief are those of the authors and/or editors of this Update, and are based solely upon the information possessed by such authors and/or editors; no inference should be drawn that such authors or editors have any special or greater knowledge about the company or companies profiled or any particular expertise in the industries or markets in which the profiled company or companies compete. The reader should verify all claims and complete his own due diligence before investing in any securities of the profiled company or companies. Neither Imperial Consulting Network Inc., Lake, nor anyone involved in the publication or dissemination of this Update is a registered investment adviser or broker/dealer. Imperial Consulting Network Inc. and Lake Makes no recommendation that the purchase of securities of the company or companies profiled in this Update are suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the company or companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree! of risk. An investor in such securities should be prepared and able to bear a loss of his or her entire investment. Nothing in this Update should be construed as an offer or solicitation to buy or sell any securities of any profiled company. Lake has been retained to provide direct marketing services for the company profiled in this Update and receives compensation for those services. Further, Lake and its employees and affiliates may own, or may purchase and sell, securities of the company or companies profiled. Lake undertakes no obligation to inform readers about the ownership or trading activities of it or its employees or affiliates in the securities of the profiled company or companies. Lake has the following compensation arrangements with the company or companies profiled in this Update: Lake receives an advertising fee ranging from $1,000 to $100,000 for each direct marketing list recommended and ordered for the dissemination of this Update.